

SUPPLEMENTAL MATERIAL


Supplemental Table 1:

Characteristics associated with the use of lipid lowering therapy associated with $\geq 50\%$ LDL-C reduction among patients with LDL-C ≥ 190 mg/dL

Variable	OR/95% CI	p value
Age (per 10-year increase)	0.95 (0.93-0.96)	<0.0001
Public versus private insurance	1 (0.96 -1.05)	0.95
Female sex	0.9 (0.87-0.93)	<0.0001
History of hypertension	1.06 (1.02-1.1)	0.0013
History of diabetes	1.24 (1.2-1.29)	<0.0001
Current smoker	1.06 (1.01-1.1)	0.0076
History of CAD	1.3 (1.25-1.34)	<0.0001
History of ischemic stroke	1.2 (1.14-1.15)	<0.0001
History of PAD	1.09 (1.04-1.15)	0.0004
Practice location (West as referent): Midwest Northeast South	0.74 (0.54-0.9) 0.87 (0.64-1.18) 0.68 (0.53-0.87)	0.045 0.36 0.002
Number of years of participation by the practice in the PINNACLE [®] registry (per one-year increase)	0.99 (0.95-1.04)	0.72

OR= odds ratio, CI = confidence interval, CAD = coronary artery disease, PAD = peripheral artery disease, PINNACLE[®] = Practice Innovation and Clinical Excellence

Supplemental Figure 1: Quarterly time trends in the use of ezetimibe in patients with LDL-C ≥ 190 mg/dL.



Supplemental Figure 2: Quarterly time trends in the use of PCSK9 inhibitor in patients with LDL-C ≥ 190 mg/dL.

